Keywords
Last Name
Institution

Michael J. Droller

TitlePROFESSOR
InstitutionMount Sinai
DepartmentUrology
Address5 East 98th Street
6th Floor
New York NY 10029
Phone212-241-4812
Fax212-987-4675
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentOncological Sciences


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Niegisch G, Lorch A, Droller MJ, Lavery HJ, Stensland KD, Albers P. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol. 2013 Sep; 64(3):355-7.
      View in: PubMed
    2. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013 Nov; 64(5):846-54.
      View in: PubMed
    3. Droller MJ. New steps forward for Urologic Oncology. Urol Oncol. 2013 Feb; 31(2):135-6.
      View in: PubMed
    4. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15.
      View in: PubMed
    5. Lavery HJ, Droller MJ. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol. 2012 Nov; 188(5):1667-75.
      View in: PubMed
    6. Droller MJ. Plagiarism. Urol Oncol. 2012 Sep; 30(5):547-8.
      View in: PubMed
    7. Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol. 2012 Aug; 188(2):361-8.
      View in: PubMed
    8. Droller MJ. A new vision for clinical research. J Urol. 2012 Jul; 188(1):8-9.
      View in: PubMed
    9. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26.
      View in: PubMed
    10. Droller MJ. It's a matter of time. J Urol. 2011 Dec; 186(6):2149-50.
      View in: PubMed
    11. Droller MJ. Preface urologic issues for the internist. Med Clin North Am. 2011 Jan; 95(1):xv-xvi.
      View in: PubMed
    12. Droller MJ. Citizenship in our profession. J Urol. 2010 Oct; 184(4):1248-50.
      View in: PubMed
    13. Zlotta AR, Cohen SM, Dinney C, Droller M, van der Kwast TH, van Rhijn BW, Bochner B, Ameil G, Jewett MA. BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):329-33.
      View in: PubMed
    14. Droller MJ. Vigilance, vigilance, vigilance. J Urol. 2010 Jan; 183(1):9-10.
      View in: PubMed
    15. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010 Feb; 105(3):300-8.
      View in: PubMed
    16. Shariat SF, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 2010 Jun; 105(12):1672-7.
      View in: PubMed
    17. Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009 Nov-Dec; 27(6):653-67.
      View in: PubMed
    18. Droller MJ. Promoting surgeon-scientists in urologic oncology: The role of our journal. Urol Oncol. 2009 Mar-Apr; 27(2):126-7.
      View in: PubMed
    19. Droller MJ. A guideline for discussion and some thoughts. J Urol. 2009 Apr; 181(4):1530-1.
      View in: PubMed
    20. Droller MJ. Peer review of guidelines, best practice statements and new documents: what this means for how we use them. J Urol. 2008 Dec; 180(6):2297-8.
      View in: PubMed
    21. Andersson L, Droller MJ. Bladder cancer: from pathogenesis to prevention. Scand J Urol Nephrol Suppl. 2008 Sep; (218):5-6.
      View in: PubMed
    22. Kakizoe T, Mucci LA, Albertsen PC, Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urol Nephrol Suppl. 2008 Sep; (218):191-212.
      View in: PubMed
    23. Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol Suppl. 2008 Sep; (218):213-33.
      View in: PubMed
    24. Andersson L, Droller MJ, Adolfsson J, Månsson W, Kirkali Z, Boffetta P, Montironi R, Malmstrom PU, Tribukait B, Grossman HB. Chairmen's summary. Scand J Urol Nephrol Suppl. 2008 Sep; (218):7-11.
      View in: PubMed
    25. Droller MJ. Urologic cancer--when is less more? J Urol. 2007 Nov; 178(5):1837-9.
      View in: PubMed
    26. Quale DZ, Droller MJ. Cancer patient advocacy: new opportunities for treatment advances. Urol Oncol. 2007 Jul-Aug; 25(4):351-2.
      View in: PubMed
    27. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
      View in: PubMed
    28. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007 Jul; 178(1):62-7.
      View in: PubMed
    29. Droller M. [Bladder cancer: understanding the disease and future implications for assessment and therapy]. Rev Med Suisse. 2006 Dec 6; 2(90):2776-8, 2781-2, 2784.
      View in: PubMed
    30. Droller MJ. Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Eur Urol. 2006 Nov; 50(5):1119-20.
      View in: PubMed
    31. Droller MJ. We need to lead and not be led. J Urol. 2006 Sep; 176(3):861-2.
      View in: PubMed
    32. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Mandeli J. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol. 2006 Jul 1; 24(19):3081-8.
      View in: PubMed
    33. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005 Dec; 66(6 Suppl 1):35-63.
      View in: PubMed
    34. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005 Dec; 66(6 Suppl 1):64-74.
      View in: PubMed
    35. Droller MJ. Biological considerations in the assessment of urothelial cancer: a retrospective. Urology. 2005 Nov; 66(5 Suppl):66-75.
      View in: PubMed
    36. Droller MJ. Changing aspects in residency education. J Urol. 2005 Nov; 174(5):1727-8.
      View in: PubMed
    37. Droller MJ. Public education: the AUA and AUA foundation. J Urol. 2005 Sep; 174(3):813.
      View in: PubMed
    38. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005 May; 95(7):961-2.
      View in: PubMed
    39. Droller MJ. When is a cancer a malignancy? J Urol. 2004 Nov; 172(5 Pt 1):1771-2.
      View in: PubMed
    40. Droller MJ. Primary care update on kidney and bladder cancer: a urologic perspective. Med Clin North Am. 2004 Mar; 88(2):309-28, x.
      View in: PubMed
    41. Canfield SE, Dinney CP, Droller MJ. Surveillance and management of recurrence for upper tract transitional cell carcinoma. Urol Clin North Am. 2003 Nov; 30(4):791-802.
      View in: PubMed
    42. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int. 2003 Aug; 92(3):223-5.
      View in: PubMed
    43. Droller MJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. J Urol. 2003 Aug; 170(2 Pt 1):671-2.
      View in: PubMed
    44. Droller MJ. Association of cyclooxygenase-2 expression with prognosis of state T1 grade 3 bladder cancer. J Urol. 2003 Aug; 170(2 Pt 1):672-3.
      View in: PubMed
    45. Droller MJ. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. J Urol. 2003 Aug; 170(2 Pt 1):670-1.
      View in: PubMed
    46. Droller MJ. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. J Urol. 2003 Aug; 170(2 Pt 1):673-4.
      View in: PubMed
    47. Droller MJ. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). J Urol. 2003 Aug; 170(2 Pt 1):674.
      View in: PubMed
    48. Droller MJ. Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. J Urol. 2003 Aug; 170(2 Pt 1):670.
      View in: PubMed
    49. Droller MJ. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. J Urol. 2003 Aug; 170(2 Pt 1):674-5.
      View in: PubMed
    50. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, Kornreich R. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. Urol Oncol. 2003 Mar-Apr; 21(2):101-4.
      View in: PubMed
    51. Droller MJ. Editorial: urothelial tumors--liberal applications of conservative approaches. J Urol. 2003 Mar; 169(3):936-7.
      View in: PubMed
    52. Helpap B, Schmitz-Dräger BJ, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters DJ, Droller MJ. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch. 2003 Apr; 442(4):309-16.
      View in: PubMed
    53. Lehrer S, Diamond EJ, Droller MJ, Stone NN, Stock RG. Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002 Dec 18; 94(24):1893; author reply 1893-4.
      View in: PubMed
    54. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol. 2002 Dec; 168(6):2431-3.
      View in: PubMed
    55. Droller MJ. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Urol. 2002 Nov; 168(5):2308-9.
      View in: PubMed
    56. Droller MJ. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. J Urol. 2002 Nov; 168(5):2302.
      View in: PubMed
    57. Droller MJ. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Urol. 2002 Nov; 168(5):2307-8.
      View in: PubMed
    58. Droller MJ. Prognostic value of p53 overexpression in T1G3 bladder tumours treated with bacillus Calmette-Guérin therapy. J Urol. 2002 Nov; 168(5):2305-6.
      View in: PubMed
    59. Droller MJ. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. J Urol. 2002 Nov; 168(5):2304-5.
      View in: PubMed
    60. Droller MJ. Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. J Urol. 2002 Aug; 168(2):854.
      View in: PubMed
    61. Droller MJ. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. J Urol. 2002 Aug; 168(2):855-6.
      View in: PubMed
    62. Droller MJ. Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. J Urol. 2002 Aug; 168(2):857-8.
      View in: PubMed
    63. Droller MJ. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. J Urol. 2002 Aug; 168(2):856.
      View in: PubMed
    64. Droller MJ. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. J Urol. 2002 Aug; 168(2):858.
      View in: PubMed
    65. Droller MJ. Risk of continued intravesical therapy and delayed cystectomy in the BCG-refractory superficial bladder cancer: an investigational approach. J Urol. 2002 Aug; 168(2):858-9.
      View in: PubMed
    66. Droller MJ. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) Test. J Urol. 2002 Aug; 168(2):856-7.
      View in: PubMed
    67. Droller MJ. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. J Urol. 2002 Aug; 168(2):852.
      View in: PubMed
    68. Droller MJ. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. J Urol. 2002 Aug; 168(2):853.
      View in: PubMed
    69. Droller MJ. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. J Urol. 2002 May; 167(5):2297-8.
      View in: PubMed
    70. Lehrer S, Stone NN, Droller MJ, Stock RG. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Urol Oncol. 2002 Mar-Apr; 7(2):73-6.
      View in: PubMed
    71. Droller MJ. Current concepts of tumor markers in bladder cancer. Urol Clin North Am. 2002 Feb; 29(1):229-34.
      View in: PubMed
    72. Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR. Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urology. 2001 Aug; 58(2):135-40.
      View in: PubMed
    73. Droller MJ. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. J Urol. 2001 May; 165(5):1811-2.
      View in: PubMed
    74. Droller MJ. Maintenance therapy for superficial bladder cancer. Oncology (Williston Park). 2001 Feb; 15(2):239-41.
      View in: PubMed
    75. Droller MJ. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. J Urol. 2001 Feb; 165(2):696-7.
      View in: PubMed
    76. Droller MJ. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. J Urol. 2001 Feb; 165(2):701-2.
      View in: PubMed
    77. Droller MJ. Markers for recurrence of superficial bladder cancer: what is valid? J Urol. 2000 Nov; 164(5):1840-1.
      View in: PubMed
    78. Droller MJ. Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. J Urol. 2000 Nov; 164(5):1840.
      View in: PubMed
    79. Droller MJ. Urology in the twenty-first century: noninvasive targeted treatments for urologic malignancies. World J Surg. 2000 Oct; 24(10):1211-4.
      View in: PubMed
    80. Droller MJ. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. J Urol. 2000 Aug; 164(2):594.
      View in: PubMed
    81. Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol. 2000 Jul; 10(4):291-9.
      View in: PubMed
    82. Droller MJ. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide. J Urol. 2000 May; 163(5):1600.
      View in: PubMed
    83. Droller MJ. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. J Urol. 2000 May; 163(5):1601.
      View in: PubMed
    84. Droller MJ. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. J Urol. 2000 May; 163(5):1602-3.
      View in: PubMed
    85. Droller MJ. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. J Urol. 2000 Feb; 163(2):665-6.
      View in: PubMed
    86. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000 Feb; 27(1):1-13, vii.
      View in: PubMed
    87. Droller MJ. Urothelial cancer--mucosally confined disease can be aggressive. J Urol. 2000 Jan; 163(1):79-80.
      View in: PubMed
    88. Droller MJ, Malmström PU. Premalignant lesions and carcinoma in situ in bladder neoplasia: introduction and overview. Scand J Urol Nephrol Suppl. 2000; (205):62-6.
      View in: PubMed
    89. Droller MJ. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. J Urol. 1999 Feb; 161(2):714-5.
      View in: PubMed
    90. Droller MJ. Markers in bladder cancer--issues to consider. J Urol. 1998 Dec; 160(6 Pt 1):2009-10.
      View in: PubMed
    91. Droller MJ. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J Urol. 1998 Nov; 160(5):1932.
      View in: PubMed
    92. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin. 1998 Sep-Oct; 48(5):269-84.
      View in: PubMed
    93. Droller MJ, Kavaler E, Landman J, Liu BC. Urinary telomerase and its possible role as a marker for bladder cancer. Keio J Med. 1998 Sep; 47(3):135-41.
      View in: PubMed
    94. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998 Sep; 52(3):398-402.
      View in: PubMed
    95. Droller MJ. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. J Urol. 1998 Aug; 160(2):620-1.
      View in: PubMed
    96. Droller MJ. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. J Urol. 1998 Aug; 160(2):618.
      View in: PubMed
    97. Droller MJ. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. J Urol. 1998 Aug; 160(2):619-20.
      View in: PubMed
    98. Droller MJ, Ekman P, Gohji K, Koiso K, Kumazawa J, Matsumura Y, Newling DW, Sylvester R, Torti FM. Standardization in pathologic assessment of transitional cell cancer of the bladder. Urol Oncol. 1998 Jul-Oct; 4(4-5):106-20.
      View in: PubMed
    99. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 1998 Feb 15; 82(4):708-14.
      View in: PubMed
    100. Droller MJ. Improved detection of recurrent bladder cancer using the bard BTA stat test. J Urol. 1998 Feb; 159(2):601-2.
      View in: PubMed
    101. Landman J, Droller MJ. Risk factors in clonal development from superficial to invasive bladder cancer. Cancer Surv. 1998; 31:5-15.
      View in: PubMed
    102. Droller MJ. Bladder cancer. J Urol. 1997 Apr; 157(4):1266-7.
      View in: PubMed
    103. Droller MJ. Medical approaches in the management of prostatic disease. Br J Urol. 1997 Apr; 79 Suppl 2:42-52.
      View in: PubMed
    104. Landman J, Kavaler E, Droller MJ, Liu BC. Applications of telomerase in urologic oncology. World J Urol. 1997; 15(2):120-4.
      View in: PubMed
    105. Kirschenbaum A, Wang JP, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC. Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncol. 1997 Jan-Feb; 3(1):3-10.
      View in: PubMed
    106. Droller MJ. Environment and the genitourinary tract. Otolaryngol Head Neck Surg. 1996 Feb; 114(2):248-52.
      View in: PubMed
    107. Droller MJ. New efforts to stage bladder cancer. J Urol. 1995 Aug; 154(2 Pt 1):385-6.
      View in: PubMed
    108. Shemtov MM, Cheng DL, Kong L, Shu WP, Sassaroli M, Droller MJ, Liu BC. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy. J Urol. 1995 Jul; 154(1):269-74.
      View in: PubMed
    109. Shirai T, Fradet Y, Huland H, Bollack C, Droller M, Janknegt R, Jones P, Kagawa S. The etiology of bladder cancer--are there any new clues or predictors of behavior? Int J Urol. 1995 Jun; 2 Suppl 2:64-75.
      View in: PubMed
    110. Liu BC, Droller MJ. Translational research in urology: From the laboratory to the clinic. Urol Oncol. 1995 Mar-Apr; 1(2):49-50.
      View in: PubMed
    111. Droller MJ. Bladder cancer: the power of study design, interpretation of data and clinical application. J Urol. 1995 Mar; 153(3 Pt 2):974-5.
      View in: PubMed
    112. Droller MJ. Bladder cancer. J Urol. 1994 Nov; 152(5 Pt 1):1434.
      View in: PubMed
    113. Droller MJ. This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J Urol. 1994 Nov; 152(5 Pt 1):1356-7.
      View in: PubMed
    114. Cheng DL, Shu WP, Choi JC, Margolis EJ, Droller MJ, Liu BC. Bacillus Calmette-Guérin interacts with the carboxyl-terminal heparin binding domain of fibronectin: implications for BCG-mediated antitumor activity. J Urol. 1994 Oct; 152(4):1275-80.
      View in: PubMed
    115. Droller MJ. Bladder cancer. J Urol. 1994 Jan; 151(1):47-8.
      View in: PubMed
    116. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin Urol. 1993 Nov; 11(4):177-92.
      View in: PubMed
    117. Gordon JN, Shu WP, Schlussel RN, Droller MJ, Liu BC. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res. 1993 Oct 15; 53(20):4971-7.
      View in: PubMed
    118. Ostad M, Weiss R, Droller M, Liu B. Ha-ras oncogene induction of invasion and metastasis is associated with the activation and redistribution of protease(s) in rat-kidney cells. Int J Oncol. 1992 Dec; 1(7):765-71.
      View in: PubMed
    119. Soloway MS, Droller MJ, Flanigan RC, Nseyo UO. Superficial bladder disease: case studies and therapeutic advances. Urology. 1992 Dec; 40(6 Suppl):11-22.
      View in: PubMed
    120. Droller MJ. Treatment of regionally advanced bladder cancer. An overview. Urol Clin North Am. 1992 Nov; 19(4):685-93.
      View in: PubMed
    121. Liu BC, Weiss RE, Gordon JN, Droller MJ. Biology of metastasis: clinical implications. Semin Surg Oncol. 1992 Sep-Oct; 8(5):267-73.
      View in: PubMed
    122. Garden RJ, Liu BC, Redwood SM, Weiss RE, Droller MJ. Bacillus Calmette-Guerin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J Urol. 1992 Sep; 148(3):900-5.
      View in: PubMed
    123. Redwood SM, Liu BC, Weiss RE, Hodge DE, Droller MJ. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer. 1992 Mar 1; 69(5):1212-9.
      View in: PubMed
    124. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Re: Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. J Urol. 1992 Feb; 147(2):474.
      View in: PubMed
    125. Levine AC, Kirschenbaum A, Droller M, Gabrilove JL. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. J Urol. 1991 Sep; 146(3):790-3.
      View in: PubMed
    126. Schlussel RN, Droller MJ, Liu BC. Type IV procollagen mRNA regulation: evidence for extracellular matrix/cytoskeleton/nuclear matrix interactions in human urothelium. J Urol. 1991 Aug; 146(2):428-32.
      View in: PubMed
    127. Stone NN, Droller MJ. Role of immunotherapy in the treatment of bladder and renal cell carcinoma. Semin Surg Oncol. 1991 Jul-Aug; 7(4):239-43.
      View in: PubMed
    128. Liu BC, Droller MJ. Biochemistry of human bladder tumor invasion. Scand J Urol Nephrol Suppl. 1991; 138:145-51.
      View in: PubMed
    129. Schwartz GK, Redwood SM, Ohnuma T, Holland JF, Droller MJ, Liu BC. Inhibition of invasion of invasive human bladder carcinoma cells by protein kinase C inhibitor staurosporine. J Natl Cancer Inst. 1990 Nov 21; 82(22):1753-6.
      View in: PubMed
    130. Weiss RE, Liu BC, Ahlering T, Dubeau L, Droller MJ. Mechanisms of human bladder tumor invasion: role of protease cathepsin B. J Urol. 1990 Sep; 144(3):798-804.
      View in: PubMed
    131. Droller MJ. Anatomic considerations in extraperitoneal approach to radical nephrectomy. Urology. 1990 Aug; 36(2):118-23.
      View in: PubMed
    132. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab. 1989 Sep; 69(3):629-32.
      View in: PubMed
    133. Irwin R, Zincke H, Droller MJ, Prout GR, Soloway MS. Treatment modalities in superficial bladder cancer. Semin Urol. 1989 Feb; 7(1 Suppl 1):1-12.
      View in: PubMed
    134. Kirschenbaum A, Stone NN, Droller MJ. Controversies in urologic oncology. Surg Clin North Am. 1988 Oct; 68(5):1105-23.
      View in: PubMed
    135. Newman LH, Tannenbaum M, Droller MJ. Muscle-invasive bladder cancer: does it arise de novo or from pre-existing superficial disease? Urology. 1988 Jul; 32(1):58-62.
      View in: PubMed
    136. Droller MJ. Photosensitization treatment in bladder cancer. J Urol. 1988 Feb; 139(2):390-1.
      View in: PubMed
    137. Droller MJ. Biologic response modifiers in genitourinary neoplasia. Cancer. 1987 Aug 1; 60(3 Suppl):635-44.
      View in: PubMed
    138. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J Clin Endocrinol Metab. 1987 Jun; 64(6):1331-3.
      View in: PubMed
    139. Kirschenbaum A, Droller MJ. Update on oncogenes and relevance in urology. Urology. 1987 Feb; 29(2):121-30.
      View in: PubMed
    140. Droller MJ. Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. J Urol. 1987 Feb; 137(2):202-6.
      View in: PubMed
    141. Mitty HA, Droller MJ, Dikman SH. Ureteral and renal pelvic metastases from renal cell carcinoma. Urol Radiol. 1987; 9(1):16-20.
      View in: PubMed
    142. Droller MJ. A rose is a rose is a rose, or is it? J Urol. 1986 Nov; 136(5):1057-8.
      View in: PubMed
    143. Droller MJ. Bacillus Calmette-Guerin in the management of bladder cancer. J Urol. 1986 Feb; 135(2):331-3.
      View in: PubMed
    144. Droller MJ, Walsh PC. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? J Urol. 1985 Dec; 134(6):1115-7.
      View in: PubMed
    145. Droller MJ, Erozan YS. Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer. J Urol. 1985 Oct; 134(4):671-4.
      View in: PubMed
    146. Droller MJ. Immunotherapy in genitourinary neoplasia. J Urol. 1985 Jan; 133(1):1-5.
      View in: PubMed
    147. Droller MJ. Immunotherapy in genitourinary neoplasia. Urol Clin North Am. 1984 Nov; 11(4):643-57.
      View in: PubMed
    148. Droller MJ, Gomolka D. Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. J Urol. 1984 Jun; 131(6):1212-7.
      View in: PubMed
    149. Droller MJ, Gomolka D. Modulation of stimulatory effects of poly(I:C) on natural cytotoxicity by anti-interferon. Cell Immunol. 1984 Jun; 86(1):242-50.
      View in: PubMed
    150. Droller MJ, Gomolka D. Macrophage depletion and manipulation of enhanced immune response in an animal model of bladder cancer. Cell Immunol. 1984 Feb; 83(2):433-41.
      View in: PubMed
    151. Droller MJ. Definitive radiation therapy and bladder cancer: do results reflect intrinsic tumor character? Prog Clin Biol Res. 1984; 162B:43-53.
      View in: PubMed
    152. Droller MJ, Walsh PC. Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? Urology. 1983 Aug; 22(2):118-22.
      View in: PubMed
    153. Feinberg AP, Vogelstein B, Droller MJ, Baylin SB, Nelkin BD. Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science. 1983 Jun 10; 220(4602):1175-7.
      View in: PubMed
    154. Droller MJ. The controversial role of radiation therapy as adjunctive treatment of bladder cancer. J Urol. 1983 May; 129(5):897-903.
      View in: PubMed
    155. Droller MJ, Gomolka D. Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer. J Urol. 1983 Mar; 129(3):625-9.
      View in: PubMed
    156. Droller MJ, Gomolka D. Expression of the cellular immune response during tumor development in an animal model of bladder cancer. J Urol. 1982 Dec; 128(6):1385-9.
      View in: PubMed
    157. Droller MJ, Gomolka D. Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. Cancer Res. 1982 Dec; 42(12):5038-45.
      View in: PubMed
    158. Droller MJ, Gomolka D. Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. Cell Immunol. 1982 Sep 1; 72(1):1-13.
      View in: PubMed
    159. Droller MJ, Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology. 1982 Sep; 20(3):256-8.
      View in: PubMed
    160. Wiley EL, Mendelsohn G, Droller MJ, Eggleston JC. Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder. J Urol. 1982 Aug; 128(2):276-80.
      View in: PubMed
    161. Droller MJ. Prostaglandins and neoplasia. J Urol. 1981 Jun; 125(6):757-60.
      View in: PubMed
    162. Droller MJ. Bladder cancer. Curr Probl Surg. 1981 Apr; 18(4):205-79.
      View in: PubMed
    163. Emmott RC, Droller MJ, Javadpour N. Studies of A, B or O (H) surface antigen specificity: carcinoma in situ and non-malignant lesions of the bladder. J Urol. 1981 Jan; 125(1):32-5.
      View in: PubMed
    164. Weissman RM, Droller MJ. Interferon: a perspective. Invest Urol. 1980 Nov; 18(3):189-96.
      View in: PubMed
    165. Owen K, Gomolka D, Droller MJ. Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. Cell Immunol. 1980 Oct; 55(2):428-35.
      View in: PubMed
    166. Droller MJ. Cancer of the testis: an overview. Urol Clin North Am. 1980 Oct; 7(3):731-3.
      View in: PubMed
    167. Droller MJ. Carcinoma of the penis; an overview. Urol Clin North Am. 1980 Oct; 7(3):783-84.
      View in: PubMed
    168. Droller MJ. Adenocarcinoma of the prostate: an overview. Urol Clin North Am. 1980 Oct; 7(3):579-81.
      View in: PubMed
    169. Droller MJ. Renal cell carcinoma: an overview. Urol Clin North Am. 1980 Oct; 7(3):675-6.
      View in: PubMed
    170. Droller MJ. Immunotherapy and genitourinary neoplasia. Urol Clin North Am. 1980 Oct; 7(3):831-46.
      View in: PubMed
    171. Droller MJ. Transitional cell carcinoma: an overview. Urol Clin North Am. 1980 Oct; 7(3):519-21.
      View in: PubMed
    172. Owen K, Gomolka D, Droller MJ. Production of prostaglandin E2 by tumor cells in vitro. Cancer Res. 1980 Sep; 40(9):3167-71.
      View in: PubMed
    173. Droller MJ, Lindgren JA, Claessen HE, Perlmann P. Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. Cell Immunol. 1979 Oct; 47(2):261-73.
      View in: PubMed
    174. Droller MJ. Bladder cancer: pebbles to reach the water. J Urol. 1979 Oct; 122(4):476-7.
      View in: PubMed
    175. Droller MJ, Borg H, Perlmann P. In vitro enhancement of natural and antibody-dependent lymphocyte-mediated cytotoxicity against tumor target cells by interferon. Cell Immunol. 1979 Oct; 47(2):248-60.
      View in: PubMed
    176. Droller MJ, Perlmann P, Schneider MU. Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. Cell Immunol. 1978 Aug; 39(1):154-64.
      View in: PubMed
    177. Pyeritz RE, Droller MJ, Bender WL, Saral R. An approach to the control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. J Urol. 1978 Aug; 120(2):253-4.
      View in: PubMed
    178. Droller MJ, Schneider MU, Perlmann P. A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. Cell Immunol. 1978 Aug; 39(1):165-77.
      View in: PubMed
    179. Droller MJ, Freiha FS. Bacterial infection of renal calculus. JAMA. 1977 Apr 4; 237(14):1467-8.
      View in: PubMed
    180. Droller MJ, Freiha FS. Localization cytology in urothelial carcinoma. Urology. 1977 Mar; 9(3):276-80.
      View in: PubMed
    181. Droller MJ. Differences in adenylate cyclase activities in murine normal cells and bladder tumor cells in tissue culture. Invest Urol. 1976 Nov; 14(3):249-52.
      View in: PubMed
    182. Droller MJ. Thrombin-induced platelet prostaglandin and cyclic AMP production and a possible intrinsic modulation of platelet function. Scand J Haematol. 1976 Sep; 17(3):167-78.
      View in: PubMed
    183. Lewin KJ, Fair WR, Steigbigel RT, Winberg CD, Droller MJ. Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol. 1976 Apr; 29(4):354-363.
      View in: PubMed
    184. Droller MJ, Remington JS. Lymphocyte and macrophage adenyl cyclase activity in animals with enhanced cell-mediated resistance to infection and tumors. Cell Immunol. 1975 Oct; 19(2):349-55.
      View in: PubMed
    185. Droller MJ, Remington JS. A role for the macrophage in in vivo and in vitro resistance to murine bladder tumor cell growth. Cancer Res. 1975 Jan; 35(1):49-53.
      View in: PubMed
    186. Bruno JJ, Taylor LA, Droller MJ. Effects of prostaglandin E2 on human platelet adenyl cyclase and aggregation. Nature. 1974 Oct 25; 251(5477):721-3.
      View in: PubMed
    187. Friedland GW, Droller MJ, Stamey TA. Obstruction of ischemic ureteropelvic junction. Urology. 1974 Oct; 4(4):439-42.
      View in: PubMed
    188. Droller MJ. An electron microscope study of the time course of platelet nucleotide, calcium, and acid phosphatase secretion. Lab Invest. 1974 Aug; 31(2):197-205.
      View in: PubMed
    189. Droller MJ. Ultrastructure of the platelet release reaction in response to various aggregating agents and their inhibitors. Lab Invest. 1973 Dec; 29(6):595-606.
      View in: PubMed
    190. Droller MJ. Ultrastructural visualization of the thrombin-induced platelet release reaction. Scand J Haematol. 1973; 11(1):35-49.
      View in: PubMed
    191. Droller MJ, Wolfe SM. Thrombin-induced increase in intracellular cyclic 3',5'-adenosine monophosphate in human platelets. J Clin Invest. 1972 Dec; 51(12):3094-103.
      View in: PubMed
    192. Droller MJ, Wolfe SM. Uncertain role of cAMP in platelet function. N Engl J Med. 1972 Apr 27; 286(17):948-9.
      View in: PubMed
    193. Droller MJ, Roth TF. An electron microscope study of yolk formation during oogenesis in Lebistes reticulatus guppyi. J Cell Biol. 1966 Feb; 28(2):209-32.
      View in: PubMed
    Droller's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067